lipoprotein fractionation test nmr

Lipoprotein(a), often written as Lp(a), is a type of lipoprotein particle containing cholesterol and a protein called apolipoprotein(a). Elevated Lp(a) levels are an independent risk factor for heart attack and stroke, even in people with normal cholesterol. Lp(a) levels are largely genetic and cannot be significantly lowered by diet or exercise alone. This test identifies individuals at heightened cardiovascular risk who may benefit from additional preventive measures or specific medications to reduce their disease risk.

Pre-beta lipoprotein is an early-stage, cholesterol-carrying particle involved in lipid metabolism. Elevated pre-beta lipoprotein levels are associated with metabolic dysfunction, insulin resistance, and increased cardiovascular risk. This test is often ordered as part of advanced lipid profiling to assess your risk for heart disease beyond standard cholesterol measurements. High levels suggest your body may not be effectively processing fats and may benefit from lifestyle modifications or treatment.

Pre-beta lipoprotein particles are small, dense lipoprotein particles involved in cholesterol transport. Large pre-beta subparticles are an emerging cardiovascular risk marker. These particles are often elevated in people with insulin resistance, elevated triglycerides, or metabolic syndrome. High levels are associated with increased atherosclerosis risk, even in individuals with normal total cholesterol. This advanced lipid test provides more detailed cardiovascular risk assessment than standard cholesterol panels.

Lipoprotein(a), or Lp(a), is a cholesterol-carrying particle in your blood that combines LDL cholesterol with a protein called apolipoprotein(a). Large Lp(a) particles may be less atherogenic (artery-damaging) than small particles. This test measures the concentration of large Lp(a) subparticles, which provides more detailed information about your cardiovascular risk. Elevated Lp(a) levels are genetically determined and are associated with increased risk of heart attack and stroke, independent of traditional cholesterol levels.

LDL cholesterol particles vary in size, and particle size pattern affects cardiovascular risk. Large, buoyant LDL particles are less atherogenic (less damaging to arteries), while small, dense LDL particles are more atherogenic. This test identifies your predominant LDL particle size pattern, providing insight beyond standard cholesterol measurements. A predominance of small, dense LDL particles is associated with higher cardiovascular risk, even with normal total LDL cholesterol. This test helps refine risk assessment and guide targeted interventions.

Small, dense LDL particles (lipoprotein beta subparticles) are a subset of low-density lipoprotein cholesterol. While total LDL level is important, the particle size matters significantly—small, dense particles penetrate artery walls more easily and are more likely to cause atherosclerosis than larger particles. High levels of small LDL particles indicate increased cardiovascular risk even with normal total cholesterol levels. This advanced lipid test provides additional insight into heart disease risk and may guide more aggressive treatment decisions for cholesterol management.

Total number of LDL particles (LDL-P) in namomoles per liter (1 nmol/L=6x10(14) particles/L)